CD22 and acute lymphoblastic leukemia: In one phase 3 trial (11), inotuzumab ozogamicin, an anti-CD22 antibody conjugated to caricomycin, showed significantly higher response rates and better progression-free survival (PFS) than standard intensive chemotherapy in adults with R/R B-ALL.